Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has announced that it is entering a royalty agreement with HealthCare Royalty Partners, boosting KPTI stock.
Karyopharm, a Massachusettes-based pharmaceutical firm, will receive an initial $75 million USD by the end of this month for HCR, and an additional $75 million USD once certain regulatory and commercial milestones have been reached. In return, HCR will receive a tiered royalty in the mid-single digits based on worldwide net revenues of Xpovio and any other future products. Xpovio is a product currently being developed by Kyropharm, which can be used to treat patients with ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.